



Nation's Leading Drug Policy Experts Demand Medication Assisted Treatment and COVID-19: Treatment Reforms

April 13, 2020 -- Austin, Texas -- During the COVID-19 pandemic, it is critical to remember that we are still in the midst of an overdose crisis. While many regulators have argued that methadone and buprenorphine policies must be deliberately restrictive due to the risk of overdose, adverse medication effects, and medication diversion, the COVID-19 crisis has forced many regulating bodies to re-evaluate these policies in order to comply with the urgent need for communities to practice social distancing and sheltering-in-place. Multiple government agencies including SAMHSA, the DEA, Medicare, and Medicaid have recently announced policy changes to allow for more flexible prescribing and dispensing. While these changes are a step forward, clinics have been either reluctant or resistant to fully implement them to the extent allowable under law. In light of the evolving pandemic and the needs of the community, we must not allow fears of overmedication and diversion to outweigh the health risks caused by patients being forced daily to congregate in large groups, or being driven to an adulterated illicit drug supply.

Close person-to-person contact and group assembly are currently actions deemed hazardous to public health. Unfortunately, "sheltering in place" is unrealistic for many people who use drugs. People who use opioids are either forced to continue to engage with the illicit drug market or must comply with prohibitive and insurmountable requirements to receive medications for Opioid Use Disorder (OUD). Many opioid users are at an increased risk of COVID-19 infection due to being immunocompromised and/or having comorbid health conditions.

Louise Vincent, President, **Urban Survivors Union**, said, "Methadone is the gold standard for treating opioid use disorder but due to stigma and discrimination many people think that using MAT is simply changing one drug for another. This is not true at all. Methadone is a lifesaving medication that has personally changed my life for the better. I attribute my ability to finish graduate school, start a non-profit and work with a national group to the stability provided by methadone."

Jess Tilley, **USU Leadership team**, "Treatment on demand could end the overdose crisis as well as substantially help flatten the curb of new COVID-19 cases. Both continue to claim lives at a shocking rate every day in this country. The ten demands that we put forth in this letter provide a undeniably comprehensive outline that supports basic human rights." Any other approach is just inhumane and based on stigma and fear based institutional idealism."

Ben Levenson, **Chairman, The Levenson Foundation**, "That it took a global pandemic to shift America's antiquated, burdensome and stigmatizing methadone and buprenorphine treatment practices to a posture more consistent with good Public Health policy is dispiriting. Nonetheless, we'll take progress wherever we find it. We strongly support these recommendations, which are consistent with best Humanitarian drug policy and practices. That the guidance arises from the patients themselves through the Drug User's Union is vital. The most important stakeholder in any medical equation is the patient, themselves – we must begin to listen in earnest to people who use if we are to meaningfully respond to the catastrophic intersection of COVID-19 and drug overdose."

Sheila Vakharia PhD., **Drug Policy Alliance**, said, "While it's heartening to see loosened policies around the initiating, prescribing, and dispensing of methadone and buprenorphine in light of COVID-19, it is clear that there are significant implementation challenges on the ground. These 10 recommendations by the Urban Survivors Union offer groundbreaking and essential policy and programmatic solutions to reduce overdose and COVID-19 risk among people who use opioids."

In order to reduce the risk of COVID-19 infection, involuntary withdrawal, and drug poisoning, the Urban Survivors Union and the undersigned organizations strongly recommend the following measures be taken immediately:

1) The only acceptable standard for discharge of patients from OUD treatment during the COVID-19 outbreak shall be violent behavior that would endanger their own health and safety or that of other patients or staff.

2) Administrative detox shall be fully suspended during the pandemic and patients shall be provided the opportunity to request dose increases as needed, given that the illicit drug market will continue to experience fluctuations and patients need access to these life-saving medications. Patient doses shall not be reduced during the transition to take-home care unless they request adjustments to their doses, or documented medical emergencies require it and patients cannot consent due to medical crises, as may be the case with severe respiratory distress resulting from COVID-19 infection.

3) Referrals for COVID-19 testing shall be made available at all opioid treatment programs (OTPs), as well as syringe service programs. Staff shall receive training to recognize the symptoms of COVID-19 and be familiarized with protocols to refer patients for further testing. Harm reduction providers can also play an essential role in "flattening the curve" of transmission by identifying cases, making

medical attention available to those who test positive, and teaching life-saving harm reduction skills to help people stay safe during this crisis. Plain language and evidence-based public health materials about COVID-19 prevention, symptom identification, and treatment should be available in locally prominent languages at all locations for participants and their communities.

4) During the COVID-19 national emergency, healthcare professionals--including doctors, nurse practitioners, physician assistants, and pharmacists--shall not be required to complete the previously-mandated training and waiver to prescribe these medications, thereby making MAT available in all settings. Prescribers shall not have limitations on the number of patients that they can treat. Naloxone and other overdose prevention tools (i.e. fentanyl test strips) shall be prescribed or made available with all dispensed medications in compliance with state law.

5) Opioid treatment programs (OTPs), prescribing clinicians, and pharmacies shall actively work to expand access to methadone treatment through the medical maintenance/office-based and pharmacy-delivery methods currently allowed by federal exception/waiver. The existing OTP regulations for the dispensing of MAT shall be temporarily adjusted to require all pharmacies to dispense these medications. This will reduce the risks of transmission associated with daily clinic attendance and person-to-person contact. In accordance with SAMHSA recommendations, lockbox requirements for take-home dispensing shall be suspended. Standard dispensing protocols for other opioid medications are deemed sufficient, since child- and tamper-proof bottles are already in use for methadone and buprenorphine. (Per SAMHSA's TIP 43, Chapter 5: "Some programs require patients to bring a locked container to the OTP when they pick up their take-home medication to hold it while in transit. This policy should be considered carefully because most such containers are large and visible, which might serve more to advertise that a patient is carrying medication than to promote safety.")

6) Take-home exception privileges shall be expanded to the maximum extent possible, limited only by available supply and operations for delivery. Any bottle checks that clinics wish to conduct shall be conducted by tele-medicine. Take-home schedules shall be authorized for individuals in all medical settings, including pharmacies and mobile vans. In light of new SAMHSA guidelines, clinics shall allow 14 to 28 days of take-home privileges to as many patients as possible. Patients testing positive for benzodiazepine or alcohol use shall be allowed the take-home privileges outlined in SAMHSA guidelines, but may be additionally required to check in via telemedicine for the purpose of decreasing the risk of adverse reactions, including overdose. Access to take-home doses is critical to keep patients engaged and retained in treatment.

7) Telehealth and service by phone shall replace any and all in-person requirements and appointments as the primary means of service provision until social distancing guidelines change. Toxicology requirements shall be suspended for the duration of telehealth-based services.

Telemedicine services shall include waived platforms, such as telephone intakes and video conferencing, as some patients may have different access needs.

8) The regulatory in-person requirements for methadone inductions shall be lifted in order to be consistent with the new policy changes for buprenorphine inductions. Clinic-based in-person appointments shall conform to social distancing requirements and OSHA guidelines for the management of the COVID-19 pandemic.

9) DEA restrictions on mobile medication units shall be revised to accommodate delivery of medications to individuals who are sequestered in their homes, are quarantined, or live in rural communities that are 15 miles or more from the nearest opioid treatment program.

10) State and federal Medicaid dollars shall be expanded to cover all costs for take-home medications not otherwise covered by insurance for patients experiencing financial hardship due to COVID-19. In states that did not expand Medicaid, the state shall be the payor of last resort.

In the interest of saving lives and adhering to existing public health protocol for management of COVID-19 transmission, it is necessary to make significant revisions to existing regulatory standards. This is a critical time to take decisive action for the protection of patients, providers, their families, and the community. As our healthcare system reaches full capacity and becomes overburdened by COVID-19-related emergencies, as seen in Italy and Spain, providers on the front lines will be forced to make life and death choices. These recommendations outline a plan of primary prevention that will minimize the burden on our healthcare system and save lives during this national emergency.

We, the undersigned, are a coalition of direct service providers, community advocates, public health officials, medical professionals, human rights groups, people in recovery, treatment professionals, members of impacted communities, and many others. We ask SAMHSA, the DEA, and all other federal, state, and local regulatory bodies and health authorities to adopt these recommendations fully and immediately in light of the COVID-19 pandemic.

Media Contact

Adam Handelsman

(512) 363-0594

adam@specopscomm.com

Organizations

Urban Survivors Union

Louise Vincent, MPH
Executive Director

National Harm Reduction Coalition

Monique Tula
Executive Director

The National Alliance for Medication-Assisted Recovery

Zachary Talbott, MSW
President
Jocelyn S. Woods, MA
Executive Director

Faces and Voices of Recovery

Patty McCarthy, M.S.
Chief Executive Officer

National Viral Hepatitis Roundtable

Lauren Canary, MPH
Director

Law Enforcement Action Partnership

Major Neill Franklin (Ret.)
Executive Director

The Levenson Foundation

Benjamin A. Levenson
Chairman

Foundation for Recovery

Dona M. Dmitrovic, MHS
Executive Director

National Council for Behavioral Health

Chuck Ingolia
President and CEO

Drug Policy Alliance

Kassandra Frederique
Managing Director, Policy Advocacy &
Campaigns

International Certification & Reciprocity Consortium

Crystal Smalldon, CCAC, CIAC, RSSW
President

Behavioral Health Association of Providers

Pete Nielsen, MA, LAADC
CEO

Center on Addiction / Partnership for Drug-Free Kids

Frederick Muench, Ph.D.
President

National Advocates for Pregnant Women

Lynn M. Paltrow, J.D.
Founder and Executive Director

Recovery Advocacy Project

Ryan Hampton
Organizing Director

Open Society Foundations

Sarah Evans
Unit Manager, Public Health Program
Kasia Malinowska-Sempruch
Director, Global Drug Policy Program

305 Psychotherapy Group

Mark Houston, LCSW
Owner and Psychotherapist

TASC

Organizations

Addiction Professionals of North Carolina

Sarah Potter, MPA
Executive Director

AIDS United

Drew Gibson, MSW
Policy Manager for HIV & Drug User Health

Alcohol & Drug Abuse Certification Board of Georgia

Amanda Finley
Executive Director

Alliance for Positive Health

Diana Aguglia
Regional Director

The BALM Training Institute for Family Recovery Services/Family Recovery Resources

Beverly A Buncher, MA, CBFRLC, PCC
Chief Executive Officer

Bay Area Workers Support

Maxine Holloway, MPH
Co-Founder

Benevolence Farm

Kristen Powers
Interim Executive Director

Better Life in Recovery/Springfield Recovery Community Center

David Stoecker, LCSW
Executive Director

BioMed Behavioral Healthcare, Inc

Brian A McCarroll DO. MS. ABAM
CEO, President

Brave Technology Coop

Gordon Casey
Chief Executive Officer

Broken No More

Tamara Olt, M.D.
Executive Director

CADA of Northwest Louisiana

Bill Rose, LAC, CCS, CCGC
Executive Director

Center for Optimal Living

Andrew Tatarsky, Ph.D.
Executive Director

Center for Popular Democracy/ Opioid Network

Jennifer Flynn Walker
Senior Director of Advocacy and Mobilization

Central Texas Harm Reduction

Richard Bradshaw
Community Outreach Leader

CheckUpandChoices.com

Reid K Hester, Ph.D.
Director, Research Division

Chicago Drug Users Union

Peter Moinichen, CADC, CODP, MAATP
Co-Founder

Chicago Recovery Alliance

Brandie Wilson
Executive Director

Choices Recovery Trainings

Ginger Ross, CRSW, NCPRSS
Owner/Trainer

Organizations

Church of Safe Injection

Kari Morissette
Director

Circle for Justice Innovations

Aleah Bacqui Vaughn
Executive Director

City of Revere - Substance Use Disorder Initiatives Office

Julia Newhall, BSW, CPS
Director

Coastal Holistic Care

Jessi Ross
Founder

Connecticut Certification Board

Jeff Quamme, MSW
Executive Director

DanceSafe

Mitchell Gomez
Executive Director

Desiree Alliance

Cristine Sardina, BWS, MSJ
Director

društvo AREAL

Janko Belin
President

ekiM For Change

Dianne Carden Glenn
Director

Exponents, Inc.

Joseph Turner, J.D.
President and CEO

Faith In Public Life

Blyth Barnow, MDiv
Harm Reduction Faith Manager

Families for Sensible Drug Policy

Carol Katz-Beyer
President

Florida Opiate Coalition- Block by Block

Bonny Batchelor
Director

Foundation for Recovery

Dona M. Dmitrovic, MHS
Executive Director

Full Circle Recovery Center, LLC

Stephanie Almeida, CDAC
Founder

Georgia Overdose Prevention

Laurie Fuggitt, RN and Robin Elliott, RN
Co-Founder

GoodWorks: North Alabama Harm Reduction

Morgan Farrington
Founder

The Grand Rapids Red Project

Stephen Alsum
Executive Director

Grayken Center for Addiction, Boston Medical Center

Michael Botticelli, MEd
Executive Director

Greater Hartford Harm Reduction Coalition Inc.

Mark A. Jenkins
Executive Director

Organizations

Guilford County Solution to the Opioid Problem

Chase Holleman, LCSW, LCAS
Program Director

Harm Reduction Action Center

Lisa Raville
Executive Director

Harm Reduction Ohio

Dennis Cauchon
President

Harm Reduction Therapy Center

Jeannie Little, LCSW
Executive Director

Health in Justice Action Lab

Leo Beletsky, JD MPH
Director

Health Professionals in Recovery

William C. Kinkle, RN, EMT-P, CRS
Co-Owner

Health Services Center, Inc.

Melissa Parker
Prevention Projects Director

Healthy Streets / Health Innovations

Mary Wheeler
Program Manager

HIPS

Tamika Spellman
Policy and Advocacy Associate

HIV/HCV Resource Center

Laura Byrne, MA
Executive Director

Hope Recovery Resources

Beth Fisher Sanders, LCSW, LCAS, MAC, CCS,
MATS
Chief Executive Officer

HRH413

Albert Park, MSW
Co-Founder

International Network of People Who Use Drugs

Judy Chang
Executive Director

Illinois Association of Behavioral Health

Sara Howe, MDA
Executive Director

Inclusion Recovery

Dan Ronken, LPC, LAC
Founder

Indiana Recovery Alliance

Kass Botts
Executive Director

Innovative Health Systems

Ross Fishman, Ph.D.
President

Instituto RIA

Zara Snapp
Co-Founder

Iowa Harm Reduction Coalition

Sarah Ziegenhorn
Executive Director

Katal Center for Health, Equity, and Justice

Gabriel Sayegh, MPH
Co-Executive Director

Organizations

The Lemire Group LLC

Dean Lemire
Owner

Lifespan Counseling

Dene Berman, Ph.D., MPH, ABPP, MAC
Director

Lysistrata Mutual Care and Collective Fund

Cora Colt
Co-Founder and Treasurer

MEDPEARL LLC

Deanna Dunn, PharmD
Owner/Pharmacist

The Middle East and North African Network of/for People who use Drugs

Hasan Taraif
Executive Director

Minnesota Recovery Connection

Wendy Jones
Executive Director

Movement for Family Power

Lisa Sangoi and Erin Coud
Co-Founders and Co-Directors

NCADD- NJ

Heather Ogden, CPRS, CRSP, CADC Intern
Advocacy Coordinator

New England Users Union

Jess Tilley
Executive Director

New Jersey Harm Reduction Coalition

Jenna Mellor
Executive Director

A New PATH, Parents for Addiction Treatment & Healing

Gretchen Burns Bergman
Executive Director

New View Addiction Recovery Educational Center

Jennifer A. Burns, MA
Executive Director

New York Center for Living

Audrey Freshman, Ph.D., LCSW, CASAC
Executive Director/Chief Clinical Officer

New York State Harm Reduction Association

Joseph Turner, J.D.
Co-Chairperson

North American Syringe Exchange Network/ Tacoma Needle Exchange

Paul A. LaKosky, Ph.D.
Executive Director

North Carolina Harm Reduction

Shelisa Howard-Martinez
Executive Director

North Carolina Survivors Union

Louise Vincent, MPH
Executive Director

Northern Berkshire EMS

Stephen Murray, BBA, NRP
Paramedic Supervisor

ONESTOP Harm Reduction Center, North Shore Health Project

Mary Doneski, MA
Program Manager

Organizations

PeerNUPS/Athens/Greece

Christos Anastasiou
Coordinator

Pennsylvania Alliance of Recovery Residences

Fred Way, MA
Executive Director

Pennsylvania Harm Reduction Coalition

Devin Reaves, MSW
Executive Director

People's Action

Sondra Youdelman
Campaigns Director

The People's Harm Reduction Alliance

Shilo Jama
Executive Director

The Perfectly Flawed Foundation

Luke Tomsha
Executive Director

Philadelphia Drug Users Union

David Tomlinson, BA
Founder

Project Point Pittsburgh

Alice Bell, LCSW
Overdose Prevention Project Coordinator

Protect Families First

Annajane Yolken
Executive Director

Provenance Counseling

Lisa S Musarra, MSW, LCSW, LCADC, ICADV
Owner

The Reach Project, Inc and Reach Medical, PLLC

Justine Waldman, MD, FACEP
Chief Executive Officer

Reframe Health and Justice

Sasanka Jinadasa
Partner

Rights & Democracy NH, Rights & Democracy VT, Rights & Democracy Institute

Kate Logan, MA/ABD
Director of Programming & Policy

R Street Institute

Carrie Wade, Ph.D., MPH
Director of Harm Reduction Policy
Chelsea Boyd, MS
Research Associate Harm Reduction Policy

San Francisco AIDS Foundation

Laura Thomas, MPH, MPP
Director of Harm Reduction Policy

The Seven Challenges LLC

Robert Schwebel, Ph.D.
Author and Program Developer

Sex Worker Advocacy Coalition

Tamika Spellman
Lead Organizer

Sex Workers Outreach Project Behind Bars

Jill McCracken, Ph.D.
Co-Director

Sex Workers Organizing Project- USA

Christa Daring
Executive Director

Organizations

The Southern Tier AIDS Program

John Barry, LMSW
Executive Director

Students for Sensible Drug Policy

Betty Aldrich
Executive Director

Students For Sensible Drug Policy Africa

Ewelle Sylvester Williams, SW
Vice Chairman

Substance Use, Policy, Education and Recovery

PAC

Haley McKee
Co-Chair

Suncoast Harm Reduction Project

Julia Negron, CAS
Founder and Lead Organizer

Tennessee Recovery Alliance

Sara Alese
Executive Director

Texas Drug User Health Alliance

Mark Kinzly
Executive Director

Texas Harm Reduction Alliance

Joy Rucker
Executive Director

Texas Harm Reduction Conference

Emily Gray
Co-Founder

Texas Overdose Naloxone Initiative

Mark Kinzly
Executive Director

Truth Pharm

Alexis Pleus
Executive Director

Ukrainian Network of People who Use Drugs

Anton Basenko, ME
Chair of the Board

University of Missouri, St. Louis

Missouri Institute of Mental Health

Claire Wood, Ph.D.
Rachel Winograd, Ph.D.
Addiction Science Faculty

Urban Survivors Union, Greensboro Chapter

Derek McCray Miller
Member

Dr. Vando Medical Services

Leonardo Vando, MD
Chief Executive Officer

Vantage Clinical Consulting LLC

Jamelia Hand, MHS, CADC, CODP
Chief Executive Officer

Vermonters for Criminal Justice Reform

Thomas Dalton, J.D., MA, LADC
Executive Director

VICTA

Lisa Peterson, LMHC, LCDP, LCDS, MAC
Chief Operating Officer

Voices of Community Activists and Leaders- New York

Jeremy Saunders
Executive Director

Organizations

Whose Corner is it Anyway

Caty Simon

Founding Co-Organizer

Women With A Vision

Christine Breland Lobre, MHS, MPH, LPC

Program Director

Zanzibar Network of People Who Use Drugs

Kassim Nyuni

Executive Director

Individuals: Professionals

Michelle Accardi-Ravid, Ph.D., Clinical Psychologist, Acting Assistant Professor, University of Washington Medical Center/ Harborview Medical Center

Chris Alba, Harm Reduction Specialist, Health Innovations Inc

Onyinye Aleri, Case Manager, Charm City Care Connection

Sarah Baranes, MD Candidate

Anton Basenko, ME, Country Focal Point: PITCH, Alliance for Public Health

Donna Beers, MSN, RN-BC, CARN, Boston Medical Center

Leo Beletsky, J.D., MPH, Health in Justice Action Lab, Northeastern University

Patricia Bellucci, Ph.D., Clinical Psychologist/Psychoanalyst

Daniel Bibeau, Ph.D., Professor of Public Health Education, University of North Carolina, Greensboro

F. Michler Bishop, Ph.D., Associate Professor; Director, Alcohol and Substance Abuse Services, Albert Ellis Institute, NY

Ricky N. Bluthenthal, Ph.D., Keck School of Medicine, University of Southern California

Elizabeth Bowen, PhD, Assistant Professor, University at Buffalo School of Social Work

Jennifer J. Carroll, Ph.D., MPH, Assistant Professor, Elon University

Sharon Chancellor, CSAC

Christie Chandler, MA, QP, North Carolina Harm Reduction Coalition

Hong Chen Chung, MD, MPH, Medical Consultant, Community Action Programs Inter-City, Inc

Seth Clark MD, MPH, Assistant Professor of Medicine and Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University

Kelley Cohill, LCSW-C

Susan E Collins, Ph.D., Co-Director, Harm Reduction Research and Treatment Center

Erica Darragh, Board Member, Students for Sensible Drug Policy; Chapter Director, DanceSafe

Jane Dicka, Health Promotion Team Coordinator, Harm Reduction Victoria

Mary Doneski, Program Manager, ONESTOP Harm Reduction Center

Patt Denning, PhD, Director of Clinical Services and Training, Harm Reduction Therapy Center

Cathy Dreifort, Harm Reduction Outreach Specialist, Shot in the Dark

Andria Efthimiou-Mordaunt MSc, Coordinator, John Mordaunt Trust

Nabila El-Bassel PhD, Director, Social Intervention Group

Taleed El-Sabawi, Assistant Professor, Elon University School of Law

Individuals: Professionals

Aaron Ferguson, The Social Exchange Podcast

Anna Fitz-James, MD, MPH

**Kathleen Foley, PhD
Ryan Fowler, CRSW, Harm Reduction Program Coordinator, HIV/HCV Resource Center**

Graeme Fox, Sonoran Prevention Works

David Frank, MMT Sociologist, Postdoctoral Research Fellow, New York University

Meryl Freedman, M.Ed, Families for Sensible Drug Policy

Ann Fuqua, BSN

Carmen Albizu Garcia, MD

Angie Geren, APP, CHt, Arizona Recovers

Louisa Gilbert, Co-Director, Social Intervention Group

Scott Goldberg, MD, Montefiore Medical Center

Judith R. Gordon, Ph.D., University of Washington

Traci Green, Ph.D., MSc, Opioid Policy Research Collaborative, the Heller School for Social Policy and Management, Brandeis University

Nancy Handmaker, Ph.D., Licensed Psychologist, Addictions Specialist

Jesse Harvey, CIPSS, RCA, Community Organizer, Church of Safe Injection

Jennifer I. Healy, Former Director, Bcbsma, Board Member, The Global Recovery Movement

**Robert Heimer, PhD, Professor of Epidemiology, Yale School of Public Health
David Himmelstein, MD**

Robert Hofmann, U.S. Movement Building Fellow, Students for Sensible Drug Policy

Heather Howard, Ph.D., Assistant Professor, Florida Atlantic University

Sheila Humphrey, Dayton Director, Harm Reduction Ohio

Lauren Jessell, MSW, Senior Research Associate

Sterling Johnson, Esq., Organizer, Black and Brown Workers Cooperative

Carol Jones, Director of Harm Reduction, Alliance for Living

Ashley Jordan, Adjunct Assistant Professor, City University of New York

Sharon Joslin, APRN, Director, Community Health Care Van, Yale University School of Medicine

Norty Kalishman MD

Mary E. Kelly, PsyD, Psychologist

Stefan Kertesz, MD, Professor, University of Alabama

Individuals: Professionals

Jennifer L Kimball, Berkshire Opioid
Addiction Prevention Collaborative

Bethea Kleykamp, MA, Ph.D., Research
Associate Professor, University of
Rochester School of Medicine and
Dentistry

Gary Langis, Harm Reduction Specialist,
Boston Medical Center
Bethany Medley, MSW, Adjunct Lecturer,
Columbia School of Social Work

Rosie Munoz-Lopez, MPH, Research
Community Engagement Facilitator,
Boston Medical Center

Janie L Kritzman, Ph.D., Lic. Psychologist,
Psychological Associates, MA; NYSPA,
Addiction Division

Dana Kurzer-Yashin, Overdose and Harm
Reduction Trainer, Harm Reduction
Coalition

David Lucas, MSW, Clinical Advisor, Center
for Court Innovation

Samuel MacMaster, Ph.D., Associate
Professor, Department of Family and
Community Health, Baylor College of
Medicine

Priya Mammen, MD, MPH, Physician,
Kensington MMT Clinic

Marilena Marchetti, Co-Director, *Liquid
Handcuffs*

JoEllen Marsha, MPA, LEAD Program
Director, CONNECT

Bethany Medley, MSW, Adjunct Lecturer,
Columbia School of Social Work

Regina McCoy, MPH, MCHES, NBC-HWC,
Professor, UNC Greensboro

Ryan McNeil, Ph.D., Assistant Professor &
Director of Harm Reduction Research, Yale
Program in Addiction Medicine, Yale
School of Medicine

Nancy Mullin, MA, PsyD Graduate Student,
California Institute of Integral Studies

Alicia Murray, DO, Addiction Psychiatrist,
General Psychiatrist

Ethan Nadelmann, Founder and former
Executive Director, Drug Policy Alliance

Daniel Nauts, MD, FASAM,
Consultant/trainer, Montana Primary Care
Association

Tammera V Nauts, LCSW, LAC, IBH
Director, Montana Primary Care
Association

Tracy R. Nichols, Ph.D., Department of
Public Health Education, University of
North Carolina, Greensboro

Danielle C. Ompad, Ph.D., Associate
Professor, New York University School of
Global Public Health

Caitlin O'Neill, Director of Harm Reduction
Services, New Jersey Harm Reduction
Coalition

Dinah Ortiz, NCSU Board Member

Bayla Ostrach, MA, PhD

Individuals: Professionals

Steven Pacheco, Program Officer, Circle for Justice Innovations Fund

Ju Nyeong Park, Assistant Scientist, Johns Hopkins University

John P Pasagiannis, Ph.D., Clinical Psychologist

Stanton Peele, J.D., Ph.D., Founder, The Life Process Program

Bonnie A Peirano, MPH, Ph.D.

Sandra F Penn, MD, FAAFP

Kim Powers, Drug User Health Outreach Coordinator, AIDS Support Group Cape Cod

Garrett Reuscher, CASAC, MSW student, Social Intern, Footsteps

Helen Redmond, LCSW, Adjunct Faculty, Silver School of Social Work, New York University, and Co-Director of *Liquid Handcuffs*

Tina Reynolds, Program Director, Circle for Justice Innovations

Kathran Richardson, PRSS, Potomac Highlands Guild

Lindsay Roberts, MSW, NCSU Board Member and Sex Worker Liaison

Patrick Roff, Curriculum and Training Developer, Prevention is Key/CARES

Lila Rosenbloom, MSW

Rene R Salazar, Ph.D., MPH, CIH, University of South Florida College of Public Health

Elizabeth A. Samuels, MD, MPH, mHS, Assistant Professor of Emergency Medicine, Brown Emergency Medicine

Vanessa Santana, Recovery Coach, Turning Point Recovery Center

Carolyn Sartor, Ph.D., Associate Professor, Yale School of Medicine

Roxanne Saucier, MPH

Jacob Schonberg, CPSS, Social Work Practitioner, UNC School of Medicine

Mark Schulz, Associate Professor, University of North Carolina, Greensboro

Mandy Sladky RN, MSN, CARN, Opioid Project Manager and OBOT RN, Public Health Seattle & King County

Samuel Snodgrass, Ph.D., Board Member, Broken No More

Nicole Spector, RN, BSN, Health Innovations Inc

Annie Steinberg, President, GW Chapter Students for Sensible Drug Policy

Dr. Laura Stern, Sage Neuroscience Center

Janet K Stoltenborg, MS, MBA, Member, Moms for All Paths to Recovery from Addiction

Phillip Stracener, NCCPSS, BSW, Harm Reduction Specialist, AIDS Leadership Foothills-Area Alliance

Gabi Teed, BSW, CRSW, Perinatal SUD Care Coordinator, Amoskeag Health

Individuals: Professionals

**Matthew Tice, LCSW, Pathways to Housing
PA**

**Denise Tomasini-Joshi, J.D., MIA, Division
Director, Open Society Foundations**

**Bruce G. Trigg, MD, Public Health and
Addiction Medicine Consultant**

**Mary Kay Villaverde, M.S., Board Member,
Families for Sensible Drug Policy**

**Ingrid Walker, Ph.D., Associate Professor,
University of Washington, Tacoma**

**GracieLee Weaver, PhD, MPH, CHES, NBC-
HWC, University of North Carolina,
Greensboro**

Steffie Woolhandler, MD, MPH

**Tyler Yates, CPSS, CADC-I, Syringe
Exchange Program Coordinator, Guilford
County Solution to the Opioid Problem**

**M. Scott Young, Research Associate
Professor, University of South Florida**

**Jon E. Zibbell, PhD, Senior Scientist, RTI
International / Emory University**

Individuals: Allies

**Sarah Beale
Jade Bower
Thomas Butler
Teri Cole-Smith
Elizabeth C. Day
Joseph Dishman
Nora Maria Fuller
Paul Gorman
Melvina Hall
Christie Hansen
Maggie Hart
Anna Herdlein
Emily Jones
Anna Kistin
Coleda Lee
Rivkah L. Meder
Whitney Meex
Bernadette Proctor
Rachel Rourke
Zach Salazar
Michael G. Seay
Kasey Snider
Zabrina Whiting**